{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:24:58Z","timestamp":1768440298082,"version":"3.49.0"},"reference-count":82,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000442","type":"journal-article","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:20:09Z","timestamp":1069384809000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Selegiline for Alzheimer's disease"],"prefix":"10.1002","author":[{"given":"Jacqueline","family":"Birks","sequence":"first","affiliation":[{"name":"University of Oxford; Centre for Statistics in Medicine; Wolfson College Linton Road Oxford UK OX2 6UD"}]},{"given":"Leon","family":"Flicker","sequence":"additional","affiliation":[{"name":"University of Western Australia; Western Australian Centre for Health & Ageing - WACHA; Royal Perth Hospital Box X2213 Perth Western Australia Australia 6847"}]}],"member":"311","published-online":{"date-parts":[[2003,1,20]]},"reference":[{"key":"10.1002\/14651858.CD000442-BIB0001|cit1","first-page":"109","article-title":"Monoamine oxidase and dementia: Treatment with an inhibitor of MAO-B activity","volume":"1","author":"Agnoli","year":"1990","journal-title":"Dementia"},{"issue":"1","key":"10.1002\/14651858.CD000442-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0924-977X(92)90033-5","article-title":"CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study","volume":"2","author":"Agnoli","year":"1992","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD000442-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1532-5415.1993.tb06942.x","article-title":"L-deprenyl in the treatment of the Alzheimer type: preliminary results","volume":"41","author":"Burke","year":"1993","journal-title":"Journal of the American Geriatrics Society"},{"issue":"11","key":"10.1002\/14651858.CD000442-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1532-5415.1993.tb07306.x","article-title":"L-deprenyl in the treatment of mild dementia of the Alzheimer type: Results of a 15-month trial","volume":"41","author":"Burke","year":"1993","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD000442-BIB0005|cit5","first-page":"238","article-title":"Selegiline slows down the decline of cognitive and electrophysiological functions in Alzheimer's disease Basic and Clinical Science of Mental and Additive Disorders","volume-title":"Bibliotheca Psychiatrica","author":"Filip","year":"1997"},{"key":"10.1002\/14651858.CD000442-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Filip V Klaschka J Analysis of the effects of selegiline (L-deprenyl) on memory in Alzheimer's disease using Sternberg's paradigm Proceedings of the 7th Congress of European College of Neuropsychopharmacology; 1994 Oct 16-21, Jerusalem 1994","DOI":"10.1016\/0924-977X(94)90249-6"},{"issue":"3","key":"10.1002\/14651858.CD000442-BIB0007|cit7","first-page":"234","article-title":"Selegiline in the treatment of Alzheimer's Disease: a long-term randomized placebo-controlled trial","volume":"24","author":"Filip","year":"1999","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"10.1002\/14651858.CD000442-BIB0008|cit8","unstructured":"Filip V Kolibas E Ceskova E Hronek J Novotna D Novotny V Selegiline in mild SDAT: results of a multi-centre, double-blind, placebo-controlled trial Neuropsychopharmacology 1991"},{"key":"10.1002\/14651858.CD000442-BIB0009|cit9","unstructured":"Filip V Kolibas L and Czech and Slovak SDAT Study Group Prague Psychiatric Center The effects of one-year administration of selegiline on behavioral and cognitive measures Proceedings of the Teach Neurology Conference; 1997 Mar 6-8, Budapest 1997"},{"key":"10.1002\/14651858.CD000442-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Finali G Piccirilli M Oliani C Piccinin GL L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients Clinical Neuropharmacology 1991 523 36","DOI":"10.1097\/00002826-199112000-00005"},{"key":"10.1002\/14651858.CD000442-BIB0011|cit11","first-page":"443","article-title":"Therapeutic strategies in Alzheimer's disease: results of the neuropsychological studies with MAO- B","volume-title":"Alzheimer's Disease And Related Disorders: Advances in the Biosciences","volume":"87","author":"Finali","year":"1993"},{"key":"10.1002\/14651858.CD000442-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Finali G Piccirilli M Oliani C Piccinin GL Alzheimer-type dementia and verbal memory performances: Influence of selegiline therapy Italian Journal of Neurological Sciences 1992 141 8","DOI":"10.1007\/BF02226963"},{"key":"10.1002\/14651858.CD000442-BIB0013|cit13","first-page":"443","article-title":"Therapeutic strategies in Alzheimer's disease: results of the neuropsychological studies with MAO- B","volume-title":"Alzheimer's Disease And Related Disorders: Advances in the Biosciences","volume":"87","author":"Finali","year":"1993"},{"key":"10.1002\/14651858.CD000442-BIB0014|cit14","unstructured":"Freedman M Rewilak D Xerri T Cohen S Gordon AS Shandling M Logan A L-deprenyl in alzheimer's disease:cognitive and behavioural effects Proceedings of the Lancet Conference; 1996 Apr 25-26, Edinburgh 1996 105"},{"issue":"3","key":"10.1002\/14651858.CD000442-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1212\/WNL.50.3.660","article-title":"L-deprenyl in Alzheimer's disease. Cognitive and behavioural effects","volume":"50","author":"Freedman","year":"1998","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD000442-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF02257674","article-title":"Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease","volume":"5","author":"Heinonen","year":"1993","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD000442-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/(SICI)1099-1166(199703)12:3<319::AID-GPS488>3.0.CO;2-Q","article-title":"Selegiline in the treatment of behavioural disturbance in Alzheimer's disease","volume":"12","author":"Lawlor","year":"1997","journal-title":"Int J Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD000442-BIB0018|cit18","unstructured":"Loeb C Albano C Selegiline - A new approach to DAT treatment Proceedings of the European Conference on Parkinson's Disease and Extrapyramidal Disorders; 1990 Jul 10-14, Rome 1990 http:\/\/www.psych.org\/clin_res\/pg_dementia_8.html"},{"key":"10.1002\/14651858.CD000442-BIB0019|cit19","first-page":"451","article-title":"L-deprenyl in Alzheimer patients of different severity: Possible preventive use","volume-title":"Alzheimer's disease and related disorders advances in the biosciences","volume":"87","author":"Smirne","year":"1993"},{"issue":"2","key":"10.1002\/14651858.CD000442-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000116655","article-title":"Effects of a MAO-B inhibitor in the treatment of Alzheimer disease","volume":"31","author":"Mangoni","year":"1991","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD000442-BIB0021|cit21","unstructured":"Martucci N Fabbrini G Fioravanti M [Monoamine oxidase and dementia: Treatment with a MAO-B inhibitor] Giornale di Neuropsicofarmacologia 1989 265 9"},{"key":"10.1002\/14651858.CD000442-BIB0022|cit22","first-page":"443","article-title":"Therapeutic strategies in Alzheimer's disease: results of the neuropsychological studies with MAO- B","volume-title":"Alzheimer's Disease And Related Disorders: Advances in the Biosciences","volume":"87","author":"Finali","year":"1993"},{"issue":"2","key":"10.1002\/14651858.CD000442-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002826-199004000-00004","article-title":"Neuropsychological effects of L-deprenyl in Alzheimer's type dementia","volume":"13","author":"Piccinin","year":"1990","journal-title":"Clinical Neuropharmacology"},{"issue":"11-12","key":"10.1002\/14651858.CD000442-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s002280050702","article-title":"Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease","volume":"55","author":"Alafuzoff","year":"2000","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000442-BIB0025|cit25","first-page":"28","article-title":"Long-term selegiline treatment reduces the progression of Alzheimer's disease: results after three years' follow-up","volume":"1","author":"Koivisto","year":"1995","journal-title":"Alzheimer's Research"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD000442-BIB0026|cit26","first-page":"S67","article-title":"Long-term, double-blind trial of selegiline in Alzheimer's disease","volume":"15","author":"Riekkinen","year":"1994","journal-title":"Neurobiology of Aging"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000442-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/S0197-4580(96)80581-1","article-title":"Efficacy and safety of selegiline in the long term treatment of patients with Alzheimer's disease","volume":"17","author":"Riekkinen","year":"1996","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD000442-BIB0028|cit28","first-page":"343","article-title":"Rationale to treat Alzheimer's disease with selegiline - can we prevent the progression of the disease?","volume-title":"Alzheimer disease: from molecular biology to therapy","author":"Riekkinen","year":"1996"},{"key":"10.1002\/14651858.CD000442-BIB0029|cit29","unstructured":"Riekkinen PJ Koivisto K Helkala EL Hanninen T Vanhanen M Aaltonen H Heinonen E Slowing down the progression of Alzheimer's disease with selegiline? Proceedings of the 15th International Congress of Gerontology; 1993 Jul 4-9, Budapest, Hungary 1993"},{"key":"10.1002\/14651858.CD000442-BIB0030|cit30","first-page":"240","article-title":"Selegiline hydrochloride: Antiparkinsonian cognition enhancer","volume":"23","author":"Anon","year":"1998","journal-title":"Drugs of the Future"},{"issue":"13","key":"10.1002\/14651858.CD000442-BIB0031|cit31","first-page":"1478-9, 1481","article-title":"Study suggests antioxidants slow decline in Alzheimer's disease","volume":"54","author":"Anon","year":"1997","journal-title":"American Journal of Health System Pharmacy"},{"issue":"8","key":"10.1002\/14651858.CD000442-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199708213370814","article-title":"Alpha-tocopherol and Alzheimer's disease","volume":"337","author":"Pincus","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD000442-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00002093-199601030-00004","article-title":"Rationale and design of a multicenter study of selegiline and a-Tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes","volume":"10","author":"Sano","year":"1996","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"Suppl","key":"10.1002\/14651858.CD000442-BIB0034|cit34","first-page":"377","article-title":"Effects of Selegiline and alpha-Tocopherol on cognitive and functional outcome measures in moderately impaired patients with Alzheimer's disease","volume":"48","author":"Sano","year":"1997","journal-title":"Neurology"},{"issue":"17","key":"10.1002\/14651858.CD000442-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease","volume":"336","author":"Sano","year":"1997","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000442-BIB0036|cit36","first-page":"A289","article-title":"Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicentre clinical trial of Selegiline and a-Tocopherol","volume":"45","author":"Sano","year":"1995","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD000442-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1017\/S1041610292001327","article-title":"A strategy of \"combination chemotherapy\" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl","volume":"4","author":"Sunderland","year":"1992","journal-title":"International Psychogeriatrics"},{"issue":"2","key":"10.1002\/14651858.CD000442-BIB0038|cit38","first-page":"145","article-title":"Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type","volume":"6","author":"Tariot","year":"1998","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD000442-BIB0039|cit39","first-page":"S136","article-title":"Combination of tacrine and selegiline in Alzheimer's disease: an open pilot study","volume":"15","author":"Alhainen","year":"1994","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD000442-BIB0040|cit40","unstructured":"Alhainen K Riekkinen P Combination of tacrine and selegiline in Alzheimer's disease an open pilot study Research advances in alzheimer's disease and related disorders 1995 299 314"},{"issue":"4","key":"10.1002\/14651858.CD000442-BIB0041|cit41","first-page":"306","article-title":"Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia","volume":"12","author":"Campi","year":"1990","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD000442-BIB0042|cit42","first-page":"376","article-title":"Selegiline versus oxiracetam in patients with Alzheimer-type dementia","volume":"12","author":"Falsaperla","year":"1990","journal-title":"Clinical Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD000442-BIB0043|cit43","first-page":"342","article-title":"The use of selegiline in Alzheimer's patients with behavior problems","volume":"52","author":"Goad","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000442-BIB0044|cit44","first-page":"5","article-title":"Selegiline (L-deprenyl) - for Alzheimer's dementia","volume":"19","author":"Hardy","year":"1992","journal-title":"On Continuing Practice"},{"issue":"1","key":"10.1002\/14651858.CD000442-BIB0045|cit45","first-page":"28","article-title":"Long-term selegiline treatment reduces the progression of Alzheimer's disease: results after three years' follow-up","volume":"?","author":"Koivisto","year":"1995","journal-title":"Alzheimer's Research"},{"issue":"3","key":"10.1002\/14651858.CD000442-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0165-1781(95)02714-8","article-title":"L-Deprenyl and physostigmine for the treatment of Alzheimer's disease","volume":"58","author":"Marin","year":"1995","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD000442-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02251133","article-title":"Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl","volume":"3","author":"Martignoni","year":"1991","journal-title":"Journal of Neural Transmission"},{"issue":"12","key":"10.1002\/14651858.CD000442-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-2007-1017117","article-title":"Brief information on an early phase-II-study with deprenyl in demented patients","volume":"20","author":"Martini","year":"1987","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000442-BIB0049|cit49","first-page":"315","article-title":"Selegiline in the treatment of mild to moderate Alzheimer-type dementia","volume":"12","author":"Monteverde","year":"1990","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD000442-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Oakley F Sunderland T Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: A pilot study International Psychogeriatrics 1997 197 206","DOI":"10.1017\/S1041610297004341"},{"key":"10.1002\/14651858.CD000442-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/089198879100400304","article-title":"A pilot study of low-dose L-deprenyl in Alzheimer's disease","volume":"4","author":"Schneider","year":"1991","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"issue":"2","key":"10.1002\/14651858.CD000442-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.150.2.321","article-title":"A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease","volume":"150","author":"Schneider","year":"1993","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000442-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Sunderland T Tariot PN Cohen RM Newhouse PA Mellow AM Mueller EA Murphy DL Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease Psychopharmacology Berl 1987 293 6","DOI":"10.1007\/BF00518180"},{"issue":"5","key":"10.1002\/14651858.CD000442-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archpsyc.1987.01800170041007","article-title":"L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition","volume":"44","author":"Tariot","year":"1987","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000442-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF00216016","article-title":"Cognitive effcts of L-deprenyl in Alzheimer's disease","volume":"91","author":"Tariot","year":"1987","journal-title":"Psychopharmacology Berl"},{"issue":"1","key":"10.1002\/14651858.CD000442-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004714-198802000-00004","article-title":"Tranylcypromine compared with L-deprenyl in Alzheimer's disease","volume":"8","author":"Tariot","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD000442-BIB0057|cit57","first-page":"S55","article-title":"Apolipoprotein E genotype in a 48 week multicenter double-blind placebo-controlled transdermal selegiline trial in mild to moderate Alzheimer disease","volume":"187","author":"Hake","year":"2001","journal-title":"JNS"},{"key":"10.1002\/14651858.CD000442-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0006-3223(88)90038-8","article-title":"Cornell scale for depression in dementia","volume":"23","author":"Alexopoulos","year":"1988","journal-title":"Biol Psychiatry"},{"key":"10.1002\/14651858.CD000442-BIB0059|cit59","first-page":"American Psychi","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD000442-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1192\/bjp.114.512.797","article-title":"The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects","volume":"114","author":"Blessed","year":"1968","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000442-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM198312013092204","article-title":"Bias in Treatment Assignment in Controlled Clinical Trials","volume":"309","author":"Chalmers","year":"1983","journal-title":"N Eng J Med"},{"key":"10.1002\/14651858.CD000442-BIB0062|cit62","first-page":"World wide evid","volume-title":"Treatment of early breast cancer. Volume 1: World wide evidence 1985-1990","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1990"},{"key":"10.1002\/14651858.CD000442-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD000442-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-4943(82)90031-0","article-title":"A new rating scale for dementia syndromes","volume":"1","author":"Gottfries","year":"1982","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1002\/14651858.CD000442-BIB0065|cit65","first-page":"218","article-title":"Clinical global impressions: ECDEU Assessment manual for psychopharmacology","volume-title":"Publication ADM 76-388.","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD000442-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1097-4679(196501)21:1<65::AID-JCLP2270210122>3.0.CO;2-I","article-title":"The nurses' observation scale for inpatient evaluation","volume":"21","author":"Honigfeld","year":"1965","journal-title":"Journal of Clinical Psycholology"},{"key":"10.1002\/14651858.CD000442-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clin Trials"},{"key":"10.1002\/14651858.CD000442-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people : self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"issue":"7","key":"10.1002\/14651858.CD000442-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.","volume":"4","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD000442-BIB0070|cit70","article-title":"Cochrane Collaboration Handbook","volume-title":"Cochrane Collaboration Handbook [updated 9 December 1996]. Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 1","year":"1997"},{"key":"10.1002\/14651858.CD000442-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"10.1002\/14651858.CD000442-BIB0072|cit72","first-page":"184","article-title":"A memory test for longitudinal measurement of mild to moderate deficits","volume":"2","author":"Randt","year":"1980","journal-title":"Clinical Neuropsycholology"},{"key":"10.1002\/14651858.CD000442-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","article-title":"The global deterioration scale for assessment of primary degenerative dementia","volume":"139","author":"Reisberg","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000442-BIB0074|cit74","volume-title":"L'examen clinique en psychologie","author":"Rey","year":"1958"},{"key":"10.1002\/14651858.CD000442-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000442-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD000442-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"M216","DOI":"10.1093\/geronj\/49.5.M216","article-title":"Assessing patient dependence in Alzheimer's disease","volume":"49","author":"Stern","year":"1994","journal-title":"Journal of Gerontology"},{"key":"10.1002\/14651858.CD000442-BIB0078|cit78","first-page":"955","article-title":"A new scale for the assessment of depressed mood in demented patients Sunderland T, Alterman IS, Yount D, Hill JL, Tariot PN, Newhouse PA, Mueller EA, Mellow AM, Cohen RM. A new scale for the assessment of depressed mood in demented patients. Am J Psychiatry 1988;145:955-959.","volume":"145","author":"Sunderland","year":"1988","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000442-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1176\/ajp.152.9.1349","article-title":"The behavior rating scale for dementia Consortium to establish a registry for Alzheimer's disease","volume":"152","author":"Tariot","year":"1995","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000442-BIB0080|cit80","volume-title":"Wechsler Memory Scale-Revised (WMS-R)","author":"Wechsler","year":"1987"},{"key":"10.1002\/14651858.CD000442-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/gps.545","article-title":"The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials","volume":"17","author":"Wilcock","year":"2002","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000442-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000442","article-title":"Selegiline for Alzheimer's disease","author":"Birks","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD000442\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T14:03:16Z","timestamp":1682604196000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD000442"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2003,1,20]]},"references-count":82,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000442","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,20]]}}}